Stockscreener 앱 받기
55.03
0.72%
-0.40
시간 외 거래:
55.03
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
BioMarin (BMRN) legal chief receives options, RSUs and tax withholding - Stock Titan
BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding - Stock Titan
BioMarin (BMRN) CEO granted 89,200 options and 62,440 RSUs in 2026 awards - Stock Titan
Price-Driven Insight from (BMRN) for Rule-Based Strategy - Stock Traders Daily
Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026 - Meyka
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
BioMarin Pharmaceutical Inc. 8-K Filing: Company Information, Address, and Stock Details (March 16, 2026) - Minichart
Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India
Wolfe Research reiterates Outperform on BioMarin stock at $95 - Investing.com
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
BioMarin stops mid-stage trials of bone disorder treatment - Reuters
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials - TipRanks
BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ) - Seeking Alpha
BioMarin (NASDAQ: BMRN) stops VOXZOGO trials in Turner, SHOX and ACAN - Stock Titan
BioMarin Pharmaceutical Stock (ISIN: US09061G1013) Gains Momentum on Voxzogo Data and $4.7B Amicus A - AD HOC NEWS
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case - ChartMill
BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Braidwell LP Acquires Shares of 528,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boone Capital Management LLC Sells 118,903 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - Sahm
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
Dodge & Cox Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
12 Best Get Rich Quick Stocks to Buy According to Hedge Funds - Insider Monkey
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Insider Monkey
Inflation Data: What is the target price for BioMarin Pharmaceutical Inc stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn
EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka
BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference - MarketBeat
BioMarin Pharmaceutical touts 13% 2025 revenue growth, Amicus deal, and 2026 pipeline catalysts at Barclays event - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Charles Greg Guyer Sells 16,486 Shares - MarketBeat
BioMarin Pharmaceutical EVP Sells Over 16,000 Shares - TradingView
BioMarin (BMRN) CTO Guyer sells 16,486 shares in open-market trade - Stock Titan
Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com UK
Jefferies reiterates Buy on BioMarin stock after DMD trial data By Investing.com - Investing.com Canada
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire
First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK
Insider sale notice for BioMarin (NASDAQ: BMRN) via Fidelity Brokerage Services - Stock Titan
BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView
BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):